Shares of Bristol Myers Squibb (BMY) are surging after the FDA approved the pharmaceutical giant's schizophrenia drug, making it the first new drug-related approach for the disease in 30 years.

Market Domination Hosts Julie Hyman and Josh Lipton report more on the story and dig into how the drug works.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written and updated by Melanie Riehl